Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study

ObjectiveThis study mainly observes the efficacy and safety of almonertinib plus chemotherapy compared with almonertinib alone in the second-line treatment of advanced non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR).MethodsIn this study, clinical data of 68 pa...

Full description

Bibliographic Details
Main Authors:	Xiaoxu Fang, Yan Xiang, Kaihua Lu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Series:	Frontiers in Oncology
Subjects:	almonertinib non-small cell lung cancer epidermal growth factor receptor mutation chemotherapy safety
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1248690/full

Similar Items

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
by: Zhi Wang, et al.
Published: (2023-10-01)

Development and Validation of a UHPLC–MS/MS Method for Quantitation of Almonertinib in Rat Plasma: Application to an in vivo Interaction Study Between Paxlovid and Almonertinib
by: Peng-fei Tang, et al.
Published: (2022-07-01)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
by: Yaming Liu, et al.
Published: (2021-05-01)

Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review
by: Xin Pan, et al.
Published: (2024-08-01)

Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR
by: Faisal A. Almalki, et al.
Published: (2021-10-01)

Cancer-associated fibroblasts induce almonertinib resistance in non-small cell lung cancer
by: Guohao Wei, et al.
Published: (2025-01-01)

Case report: A patient with EGFR L861Q positive adenosquamous lung carcinoma transforming into large cell neuroendocrine cancer after treatment with Almonertinib
by: Kele Cheng, et al.
Published: (2025-02-01)

Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series
by: Yuhai Zhang, et al.
Published: (2022-11-01)

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report
by: Hai Pan, et al.
Published: (2023-05-01)

Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway
by: Teng Chen, et al.
Published: (2024-07-01)

Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway
by: Chen Shi, et al.
Published: (2024-03-01)

Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
by: Qian Zhou, et al.
Published: (2023-03-01)

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
by: Lucheng ZHU, et al.
Published: (2021-05-01)

Successful rapid improvement of acute respiratory distress syndrome induced by EGFR-mutated non-small cell lung cancer with almonertinib: a case report
by: Cheng Sun, et al.
Published: (2024-09-01)

Optimization of a sensitive and reliable UPLC-MS/MS method to simultaneously quantify almonertinib and HAS-719 and its application to study the interaction with nicardipine
by: Dongxin Chen, et al.
Published: (2024-12-01)

Modulation of almonertinib resistance in non-small cell lung cancer by cancer-associated fibroblasts through HK2-mediated glycolysis and SKP2 signaling
by: Guohao Wei, et al.
Published: (2025-02-01)

Almonertinib-induced interstitial lung disease in an NSCLC patient co-harboring EGFR Ex19del mutation and MET de novo amplification: a case report and literature review
by: Wenjing Yang, et al.
Published: (2025-02-01)

The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression during third‐generation EGFR‐TKI treatment: a retrospective study
by: Yu Zhang, et al.
Published: (2024-08-01)

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
by: Gang Shen, et al.
Published: (2021-12-01)

Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer
by: XU Wenwen, et al.
Published: (2021-12-01)

Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study
by: Chien‐Yu Lin, et al.
Published: (2023-07-01)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Qiang Wu, et al.
Published: (2021-04-01)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
by: Ya Chen, et al.
Published: (2021-04-01)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
by: Chen Chen, et al.
Published: (2020-03-01)

Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
by: Yaping Long, et al.
Published: (2022-02-01)

Epidermal Growth Factor Receptor Mutations and Radiotherapy  in Non-small Cell Lung Cancer
by: Xing ZHONG, et al.
Published: (2013-03-01)

Connexins in epidermal health and diseases: insights into their mutations, implications, and therapeutic solutions
by: S. Suheda Yasarbas, et al.
Published: (2024-05-01)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
by: Yingying Jiang, et al.
Published: (2023-05-01)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
by: Zhengyu Yang, et al.
Published: (2021-08-01)

Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis
by: Chaoyu HONG, et al.
Published: (2016-12-01)

Methotrexate-induced epidermal necrosis following intrathecal chemotherapy: A case report
by: Brad R. Woodie, BS, et al.
Published: (2025-02-01)

Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis
by: Renxian Xie, et al.
Published: (2023-09-01)

Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
by: Akinaru Yamamoto, et al.
Published: (2020-11-01)

Napsin A and Thyroid Transcription Factor-1-Positive Cerebellar Tumor with Epidermal Growth Factor Receptor Mutation
by: Taiji Kuwata, et al.
Published: (2011-12-01)

Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis
by: Wu P, et al.
Published: (2018-10-01)

Efficacy of first-line oxaliplatin-based chemotherapy regimens depending on the KRAS mutation status
by: M. Yu. Fedyanin, et al.
Published: (2018-05-01)

Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
by: Sang Hwa Lee, et al.
Published: (2015-11-01)

Palliative Gastrectomy Plus Chemotherapy versus Chemotherapy Alone for Incurable Advanced Gastric Cancer: A Meta-Analysis [Corrigendum]
by: Wu P, et al.
Published: (2024-01-01)

Immunotherapy plus chemotherapy versus chemotherapy alone in the first-line treatment for advanced gastric cancer/gastroesophageal junction cancer: a real-world retrospective study
by: Qian Xu, et al.
Published: (2024-11-01)